Loading...
XAMS
PHARM
Market cap531mUSD
Apr 11, Last price  
0.69EUR
1D
-0.72%
1Q
-24.44%
Jan 2017
217.05%
Name

Pharming Group NV

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
2.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
58.66%
Rev. gr., 5y
9.68%
Revenues
287m
+16.95%
479,681194,0101,006,021924,3531,570,290762,0693,886,98014,035,7609,450,68925,762,43911,838,27816,693,660107,517,335154,575,611189,333,721228,394,666189,853,037205,622,000245,316,000286,887,160
Net income
-11m
L+0.91%
000000000000028,589,56740,544,62737,746,00015,996,00013,674,000-10,548,000-10,644,363
CFO
-2m
L-89.63%
00000000000045,844,23046,186,22774,555,29190,977,07336,125,76722,897,000-17,302,000-1,795,000
Earnings
May 06, 2025

Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
URL
https://www.pharming.com/
IPO date
Jul 02, 1998
Employees
332
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
286,887
16.95%
245,316
19.30%
205,622
8.31%
Cost of revenue
297,310
181,627
201,912
Unusual Expense (Income)
NOPBT
(10,423)
63,689
3,710
NOPBT Margin
25.96%
1.80%
Operating Taxes
2,427
(1,464)
1,313
Tax Rate
35.39%
NOPAT
(12,850)
65,153
2,397
Net income
(10,644)
0.91%
(10,548)
-177.14%
13,674
-14.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,281
BB yield
-2.98%
Debt
Debt current
7,044
5,440
5,233
Long-term debt
130,351
199,228
194,769
Deferred revenue
Other long-term liabilities
2
Net debt
(28,905)
(19,154)
(17,071)
Cash flow
Cash from operating activities
(1,795)
(17,302)
22,897
CAPEX
(763)
(1,464)
(1,977)
Cash from investing activities
31,618
(129,388)
5,323
Cash from financing activities
(34,412)
(941)
(4,982)
FCF
(12,434)
50,235
(4,277)
Balance
Cash
162,067
213,424
207,342
Long term investments
4,233
10,398
9,731
Excess cash
151,956
211,556
206,792
Stockholders' equity
(257,589)
(260,372)
(257,659)
Invested Capital
580,270
650,698
626,892
ROIC
10.20%
0.49%
ROCE
16.32%
1.00%
EV
Common stock shares outstanding
689,188
657,021
70,714
Price
0.93
-10.19%
1.03
-4.98%
1.08
39.87%
Market cap
637,498
-5.80%
676,731
782.84%
76,654
41.07%
EV
608,593
657,577
59,583
EBITDA
5,089
79,614
16,898
EV/EBITDA
119.59
8.26
3.53
Interest
8,737
5,964
5,358
Interest/NOPBT
9.36%
144.42%